Company
Vifor Pharma
Vifor Pharma has 18 drugs tracked on RxWires: 8 post-market, 3 in Phase 3, 4 in Phase 2, 3 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Ferrous fumarate | Post-Market | Anemia |
| Ferinject | Post-Market | Iron Deficiency |
| patiromer | Post-Market | Hyperkalemia |
| Ferli-6® (Continental Pharm co., ltd.) | Post-Market | Anemia |
| ferric carboxymaltose | Post-Market | Restless Leg Syndrome |
| Ferricarboxymaltose | Post-Market | Idiopathic Pulmonary Arterial Hypertension |
| FEFINJECT | Post-Market | Cerebral Aneurysm Unruptured |
| ARM A : IV iron + epoietin zeta | Post-Market | Solid Cancer Metastatic Disease |
| FCM (Ferric carboxymaltose) high ferritin target | Phase 3 | Iron Deficiency Anaemia |
| Difelikefalin Injection | Phase 3 | Uremic Pruritus |
| Broncho-Vaxom | Phase 3 | Atopic Dermatitis |
| VIT-2763 120 mg | Phase 2 | Sickle Cell Disease |
| 1.25 g PA21 (250 mg iron) | Phase 2 | Chronic Kidney Disease |
| VIT-2763 60 mg QD | Phase 2 | Beta-Thalassemia |
| VIT-2763 once a day (QD) | Phase 2 | Beta-Thalassemia |
| PA21 and Losartan with Food | Phase 1 | Drug Interaction Potentiation |
| Vamifeport Formulation 1 | Phase 1 | Healthy |
| PA21 and Omeprazole with food | Phase 1 | Healthy |
Latest
No recent events.
Follow Vifor Pharma on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.